Fresenius SE & Co. (OTCMKTS:FSNUY) Trading Down 0.9% – Should You Sell?

Fresenius SE & Co. (OTCMKTS:FSNUY) shares fell 0.9% during trading on Friday . The company traded as low as $13.81 and last traded at $13.8220. 13,539 shares traded hands during trading, a decline of 56% from the average session volume of 30,851 shares. The stock had previously closed at $13.95.

Analyst Ratings Changes

A number of brokerages recently issued reports on FSNUY. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Monday, October 27th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Down 0.9%

The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.00. The firm’s 50-day moving average is $14.77 and its 200-day moving average is $13.52.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02. Fresenius SE & Co. had a return on equity of 9.72% and a net margin of 5.26%.The business had revenue of $6.29 billion for the quarter, compared to the consensus estimate of $6.38 billion. Sell-side analysts predict that Fresenius SE & Co. will post 0.79 EPS for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.